S'abonner

STAT6 gain-of-function variant exacerbates multiple allergic symptoms - 04/05/23

Doi : 10.1016/j.jaci.2022.12.802 
Ichiro Takeuchi, MD a, b, , Kumiko Yanagi, DDSc, PhD c, , Shuji Takada, PhD d, Toru Uchiyama, MD, PhD e, Arisa Igarashi, PhD c, f, Kenichiro Motomura, MD, PhD f, Yuka Hayashi, MD f, Naoko Nagano, MD f, Ryo Matsuoka, MD f, Hiroki Sugiyama, MD f, Takako Yoshioka, MD, PhD g, Hirohisa Saito, MD, PhD f, Toshinao Kawai, MD, PhD e, Yumiko Miyaji, MD, PhD h, Yusuke Inuzuka, MD h, Yoichi Matsubara, MD, PhD i, Yukihiro Ohya, MD, PhD h, Toshiaki Shimizu, MD, PhD b, Kenji Matsumoto, MD, PhD f, Katsuhiro Arai, MD, PhD a, h, , Ichiro Nomura, MD, PhD h, j , Tadashi Kaname, MD, PhD c , Hideaki Morita, MD, PhD f, h,
a Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan 
b Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan 
c Department of Genome Medicine, National Research Institute for Child Health and Development, Tokyo, Japan 
d Department of Systems BioMedicine, National Research Institute for Child Health and Development, Tokyo, Japan 
e Division of Immunology, National Center for Child Health and Development, Tokyo, Japan 
f Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan 
g Department of Pathology, National Center for Child Health and Development, Tokyo, Japan 
h Allergy Center, National Center for Child Health and Development, Tokyo, Japan 
i National Research Institute for Child Health and Development, Tokyo, Japan 
j Division of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, Tokyo, Japan 

∗∗Corresponding author: Hideaki Morita, MD, PhD, or Tadashi Kaname, MD, PhD, or Ichiro Nomura, MD, PhD, National Research Institute for Child Health and Development, Tokyo, Okura 2-10-1, Setagaya Ward, Tokyo 157-8535, Japan.National Research Institute for Child Health and DevelopmentTokyo, Okura 2-10-1Setagaya WardTokyo157-8535Japan∗∗∗Katsuhiro Arai, MD, PhD, Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Okura 2-10-1, Setagaya Ward, Tokyo, 157-8535, Japan.Center for Pediatric Inflammatory Bowel DiseaseDivision of GastroenterologyNational Center for Child Health and DevelopmentOkura 2-10-1, Setagaya WardTokyo157-8535Japan

Abstract

Background

Allergic diseases were long considered to be complex multifactorial disorders. However, recent findings indicate that severe allergic inflammation can be caused by monogenic immune defects.

Objectives

We sought to clarify the molecular pathogenesis of a patient with early-onset multiple allergic diseases, a high serum IgE level, hypereosinophilia, treatment-resistant severe atopic dermatitis with increased dermal collagen fiber deposition, and eosinophilic gastrointestinal disorder with numerous polypoid nodules.

Methods

A missense variant in STAT6 was identified, and its function was examined using peripheral blood, transfected HEK293 cells, lymphoblastoid cell lines, and knock-in mice with the corresponding mutation.

Results

Whole-exome sequencing identified a de novo heterozygous missense variant in signal transducer and activator of transcription 6 (STAT6) (p.Asp419Asn). Luciferase reporter assay revealed that the transcriptional activity of this STAT6 mutant was upregulated even without IL-4 stimulation. Phosphorylation of STAT6 was not observed in either the patient’s TH2 cells or lymphoblastoid cell lines without stimulation, whereas it was induced more strongly in both by IL-4 stimulation compared with healthy controls. STAT6 protein was present in the nuclear fraction of the lymphoblastoid cell lines of the patient even in the absence of IL-4 stimulation. The patient’s gastric mucosa showed upregulation of STAT6-, fibrosis-, and germinal center formation–related molecules. Some of the knock-in mice with the corresponding mutation spontaneously developed dermatitis with skin thickening and eosinophil infiltration. Moreover, serum IgE levels and mRNA expression of type 2 cytokines were increased in the knock-in mice—with or without development of spontaneous dermatitis—compared with the wild-type mice.

Conclusions

A novel STAT6 gain-of-function variant is a potential cause of primary atopic disorders.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : STAT6, hyper-IgE syndrome, hypereosinophilia, primary atopic disorders, atopic dermatitis, eosinophilic gastrointestinal disorder

Abbreviations used : EGID, EoG, GOF, LCL, PAD, STAT6, WT


Plan


 This study was supported in part by Initiative on Rare and Undiagnosed Diseases (grant nos. 19ek0109301s and 20ek0109301h) from the Japanese Agency for Medical Research and Development (AMED); National Grants-in-Aid to the National Center for Child Health and Development (grant nos. 2019A-3 [to K.A.], 2020B-10 [to I.T.], 2020B-2 [to K.M.], #29-2 [to H.M.], and 2022B-11 [to H.M.]); a Health, Labor and Welfare Sciences Research Grant for Research on Policy Planning and Evaluation for Rare and Intractable Diseases, from the Ministry of Health, Labor and Welfare (grant no. 20FC1016 [to I.N.]); and a Health, Labor and Welfare Sciences Research Grant (grant no. 21FE2001 [to H.M.]).
 Data availability: The data sets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
 Ethical considerations: This report was approved by the Institutional Review Board of the National Center for Child Health and Development, Tokyo, Japan (#378, #725, #926). Written informed consent from the patient’s parents and assent from the patient were obtained when appropriate. All animal protocols were approved by the Animal Care and Use Committee of the National Research Institute for Child Health and Development, Tokyo, Japan (#A2017-006-C03). Recombinant DNA experiments were conducted in accordance with the approved protocol (#17-3).
 Disclosure of potential conflict of interest: H. Morita has received a research grant from GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 151 - N° 5

P. 1402 - mai 2023 Retour au numéro
Article précédent Article précédent
  • Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations
  • Maria Elena Maccari, Pascal Schneider, Cristian Roberto Smulski, Andrea Meinhardt, Fernando Pinto, Luis Ignacio Gonzalez-Granado, Catharina Schuetz, Mauricio Pablo Sica, Miriam Gross, Ilka Fuchs, Patrick Kury, Maximilian Heeg, Tatjana Vocat, Laure Willen, Caroline Thomas, Regina Hühn, Aude Magerus, Myriam Lorenz, Klaus Schwarz, Frederic Rieux-Laucat, Stephan Ehl, Anne Rensing-Ehl
| Article suivant Article suivant
  • Importance of mucus burden and mucociliary impairment in asthma
  • Natsuko Nomura, Hisako Matsumoto, Hironobu Sunadome, Tsuyoshi Oguma, Toyohiro Hirai

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.